Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06677307
PHASE1/PHASE2

A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110

Sponsor: Korro Bio, Inc.

View on ClinicalTrials.gov

Summary

The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).

Official title: A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2025-01-13

Completion Date

2026-12

Last Updated

2025-12-15

Healthy Volunteers

Yes

Interventions

DRUG

KRRO-110

KRRO-110 drug product, IV

Locations (5)

The Prince Charles Hospital

Brisbane, Queensland, Australia

Nucleus Network Pty Ltd

Melbourne, Victoria, Australia

St. Vincent's Hospital Melbourne

Melbourne, Victoria, Australia

New Zealand Clinical Research

Auckland, New Zealand

New Zealand Clinical Research

Christchurch, New Zealand